Phreesia, Inc. $PHR Shares Bought by Champlain Investment Partners LLC

Key Points

• Champlain Investment Partners LLC increased its stake in Phreesia by 20% during Q1, owning approximately 2.9 million shares valued at $75.3 million.
• Over 90% of Phreesia's shares are held by institutional investors, indicating strong financial support and interest from major funds.
• Phreesia reported a revenue increase of 14.5% year-over-year for the last quarter, surpassing consensus estimates and emphasizing its growth potential.

Champlain Investment Partners LLC lifted its stake in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 20.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,946,489 shares of the company's stock after acquiring an additional 490,340 shares during the period. Champlain Investment Partners LLC owned 5.01% of Phreesia worth $75,312,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in PHR. American Century Companies Inc. boosted its stake in shares of Phreesia by 3,741.9% during the first quarter. American Century Companies Inc. now owns 983,440 shares of the company's stock valued at $25,137,000 after acquiring an additional 957,842 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its position in Phreesia by 133.6% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 1,271,832 shares of the company's stock worth $31,999,000 after buying an additional 727,384 shares during the period. Nuveen LLC purchased a new position in Phreesia during the first quarter worth about $14,206,000. Park West Asset Management LLC purchased a new position in Phreesia during the fourth quarter worth about $10,657,000. Finally, Victory Capital Management Inc. purchased a new position in Phreesia during the first quarter worth about $10,782,000. Institutional investors and hedge funds own 92.10% of the company's stock.

Insider Buying and Selling at Phreesia

In related news, Director Michael Weintraub sold 7,431 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $27.51, for a total value of $204,426.81. Following the completion of the sale, the director directly owned 143,039 shares in the company, valued at approximately $3,935,002.89. The trade was a 4.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP David Linetsky sold 23,729 shares of the business's stock in a transaction that occurred on Friday, June 27th. The shares were sold at an average price of $28.50, for a total value of $676,276.50. Following the completion of the sale, the senior vice president owned 193,510 shares of the company's stock, valued at approximately $5,515,035. This trade represents a 10.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,327 shares of company stock valued at $2,031,647 in the last three months. Corporate insiders own 5.50% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently commented on PHR. DA Davidson upgraded Phreesia to a "strong-buy" rating in a report on Tuesday, July 22nd. Truist Financial raised their price target on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, May 29th. Wall Street Zen raised Phreesia from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st. Citigroup reissued a "buy" rating on shares of Phreesia in a research note on Wednesday, May 28th. Finally, KeyCorp lifted their price target on Phreesia from $28.00 to $35.00 and gave the company an "overweight" rating in a report on Monday, July 14th. One investment analyst has rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $32.58.

Phreesia Stock Up 1.5%

Shares of Phreesia stock opened at $30.85 on Wednesday. The stock has a market cap of $1.84 billion, a PE ratio of -41.68 and a beta of 0.71. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $31.46. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.02. The business has a fifty day simple moving average of $27.68 and a 200 day simple moving average of $26.43.

Phreesia (NYSE:PHR - Get Free Report) last released its quarterly earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.06. The firm had revenue of $115.94 million for the quarter, compared to the consensus estimate of $115.00 million. Phreesia had a negative return on equity of 16.23% and a negative net margin of 9.83%.The company's revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.05) EPS. Research analysts predict that Phreesia, Inc. will post -1.1 EPS for the current year.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

Want to see what other hedge funds are holding PHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phreesia, Inc. (NYSE:PHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.